Canadian biotechnology startup Novel Biotechnology, headquartered in Toronto, has successfully raised $2.5 million in Seed funding. This funding will propel the expansion of the company's plasmid services business and accelerate its research and development initiatives in the DNA production sector. Novel Biotechnology, under the leadership of CEO Pankaj Khanna, CTO Matthew Weinstock, and CFO Konstantin Rodionov, is revolutionizing the field of DNA production with its NBx platform, ensuring increased productivity, speed, and quality to meet the needs of the biopharmaceutical industry, particularly in addressing DNA-related diseases. The company has already achieved significant milestones, including the development of its proprietary strain, proof of concept with multiple plasmid constructs, and the generation of substantial revenue through its services business. The commercial launch of NBx for plasmid manufacturing is set for Q4, 2023, marking an exciting new phase for Novel Biotechnology.